No profile data available.
Braveheart Bio, Inc. (BRVE) is a listed company, based in San Francisco, United States, with about 49 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$66.05 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $1.80 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM.
Braveheart Bio reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$1.80 billion as of October 9, 2026.